Radiant Biotherapeutics Secures $2M Grant for Next-Gen HIV Biologics

Industry Partnerships & Commercialization (IP&C) at The Hospital for Sick Children (SickKids) is pleased to share that Radiant Biotherapeutics, a biotechnology start-up based on a foundational IP from the lab of Dr. Jean-Philippe Julien at SickKids and Dr. Bebhinn Teanor at the University of Toronto, has secured a $2M grant from the Bill & Melinda Gates Foundation. This generous funding will catalyze a transformative two-year project focused on the development of next-generation HIV biologics using Radiant’s antibody technology platform – Multabody, which unveiled an $8 million seed financing and two significant pharmaceutical partnerships.

The project holds the potential to reshape traditional HIV therapies by addressing the virus’s high mutation rate and underscores the substantial impact of collaborative partnerships.

Learn more about this exciting venture.

Share this post